We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Quarterly updates to the emergency presentations of cancer data by Public Health England.
Chief Medical Officer for England, Professor Chris Whitty's annual reports and lectures on medicine and public health.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
Information on the programme, including commissioning, quality assurance, education and training.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
The characteristics, diagnosis, management, surveillance and epidemiology of Pseudomonas aeruginosa.
Information on depleted uranium (DU) including what it is, its uses, health effects and protection from exposure.
Guidance for living safely with respiratory infections, including coronavirus (COVID-19).
Information for clinicians on the characteristics, diagnosis and epidemiology of infections caused by Chlamydia psittaci.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Information and resources to improve oral health and reduce inequalities in England.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.